<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02548195</url>
  </required_header>
  <id_info>
    <org_study_id>gemoxicc</org_study_id>
    <nct_id>NCT02548195</nct_id>
  </id_info>
  <brief_title>Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma</brief_title>
  <official_title>Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate of adjuvant therapy using oxaliplatin and gemcitabine (GEMOX regimen) versus
      capecitabine alone chemotherapy in patients who underwent curative surgery for intrahepatic
      cholangiocarcinoma (ICC) -- a randomized control study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      chemotherapy: GEMOX vs capecitabine alone; adjuvant settings; primary endpoint:
      recurrence-free survival (RFS); second endpoint: overall survival after surgery (OS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>from the date of surgery to the date of tumor recurrence up to 36 months after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from the date of surgery to the date of death up to 36 months after surgery</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events and severe adverse events</measure>
    <time_frame>from the date of first dosage to safety follow-up visit (30 days after the last dosage)</time_frame>
    <description>All toxicities will be graded by CTCAE v4</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>GEMOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2; every three weeks for 6-8 cycles in total.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin and gemcitabine</intervention_name>
    <description>oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2 every three weeks for 6-8 cycles in total.</description>
    <arm_group_label>GEMOX</arm_group_label>
    <other_name>oxaliplatin</other_name>
    <other_name>gemcitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.</description>
    <arm_group_label>Capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG PSâ‰¤1;

          -  pathologically confirmed adenocarcinoma of bile duct;

          -  R1 resection or R0 resection with these risk factors: lymph node metastasis, lymphatic
             vessel or blood vessel invasion, multiple tumors, tumor size &gt;5 cm, preoperative
             CA199&gt;200 U/mL.

          -  postoperative liver function Child Pugh Class A, leukocyte count&gt;1.5*10^9/L, platelet
             count&gt;100*10^9/L, serum alanine aminotransferase &lt;1.5*ULN

          -  no tumor recurrence or metastasis on baseline examination

          -  no history of radiotherapy or intervention therapy

        Exclusion Criteria:

          -  hepatocellular carcinoma, mixed carcinoma of ICC and HCC, or hilar cholangiocarcinoma

          -  distant metastasis

          -  prothrombin time &gt;14s

          -  severe cardiopulmonary dysfunction

          -  severe renal dysfunction

          -  bone marrow suppression before the initiation of therapy

          -  allergic to fluorouracil, gemcitabine, or platinum

          -  gemcitabine was used in combination with radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinpei Huang</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hui-Chuan Sun, MD, PhD</last_name>
    <phone>+86 21 04041990</phone>
    <phone_ext>610559</phone_ext>
    <email>sun.huichuan@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mei-Ling Li</last_name>
    <email>livercongress@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei-Ling Li</last_name>
      <phone>+86 21 64041990</phone>
      <email>livercongress@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Hui-Chuan Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.</citation>
    <PMID>22237781</PMID>
  </reference>
  <results_reference>
    <citation>Cho SY, Park SJ, Kim SH, Han SS, Kim YK, Lee KW, Lee SA, Hong EK, Lee WJ, Woo SM. Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann Surg Oncol. 2010 Jul;17(7):1823-30. doi: 10.1245/s10434-010-0938-y. Epub 2010 Feb 18.</citation>
    <PMID>20165987</PMID>
  </results_reference>
  <results_reference>
    <citation>Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. Lancet Oncol. 2014 Dec;15(13):1481-92. doi: 10.1016/S1470-2045(14)70486-3. Epub 2014 Nov 12.</citation>
    <PMID>25456367</PMID>
  </results_reference>
  <results_reference>
    <citation>Patt YZ, Jones DV Jr, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol. 1996 Aug;14(8):2311-5.</citation>
    <PMID>8708722</PMID>
  </results_reference>
  <results_reference>
    <citation>Ducreux M, Van Cutsem E, Van Laethem JL, Gress TM, Jeziorski K, Rougier P, Wagener T, Anak O, Baron B, Nordlinger B; EORTC Gastro Intestinal Tract Cancer Group. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer. 2005 Feb;41(3):398-403.</citation>
    <PMID>15691639</PMID>
  </results_reference>
  <results_reference>
    <citation>Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.</citation>
    <PMID>20375404</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2015</study_first_submitted>
  <study_first_submitted_qc>September 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2015</study_first_posted>
  <last_update_submitted>September 11, 2015</last_update_submitted>
  <last_update_submitted_qc>September 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Hui-Chuan Sun</investigator_full_name>
    <investigator_title>Vice Director of the Department of Liver Surgery</investigator_title>
  </responsible_party>
  <keyword>GEMOX</keyword>
  <keyword>intrahepatic cholangiocarcinoma</keyword>
  <keyword>adjuvant therapy</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>capecitabine</keyword>
  <keyword>curative surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

